Search company, investor...
Cato Research company logo

Cato Research

Founded Year



Merger | Merged

About Cato Research

Cato Research is a provider of regulatory and clinical research services.

Headquarters Location

Westpark Corporate Center 4364 South Alston Avenue

Durham, North Carolina, 27713,

United States


Missing: Cato Research's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cato Research's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cato Research

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cato Research is included in 2 Expert Collections, including Clinical Trials Tech.


Clinical Trials Tech

341 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Biopharma Tech

326 items

Cato Research Patents

Cato Research has filed 4 patents.

The 3 most popular patent topics include:

  • Data centers
  • Electric power distribution
  • Electrical engineering
patents chart

Application Date

Grant Date


Related Topics




Electric power distribution, Energy conservation, Data centers, Mechanical power control, Electrical engineering


Application Date


Grant Date



Related Topics

Electric power distribution, Energy conservation, Data centers, Mechanical power control, Electrical engineering



Latest Cato Research News

CATO SMS Appoints Regulatory Strategy Leader

Jun 9, 2021

CATO SMS Appoints Regulatory Strategy Leader CARY, N.C. Jun 9, 2021 4:57 AM EDT CARY, N.C., June 9, 2021 /PRNewswire/ -- CATO SMS ,a global provider of specialized clinical research solutions, announced today that it has appointed Dr. Ernesto Vera-Sanchez to vice president of regulatory strategy and head of Good Practices (GxP) consulting services. Dr. Vera-Sanchez, who brings to CATO SMS nearly 20 years of global regulator and inspectorate experience, will spearhead CATO SMS' quality and safety initiatives serving the company's biopharmaceutical clients. Prior to joining CATO SMS, Dr. Vera-Sanchez achieved an accomplished career at the Ministry of Health, Spanish Agency of Medicines and Medical Devices (AEMPS), where he was promoted to positions of increasing responsibility. He recently served as head of Inspectorate of Good Clinical Practice (GCP) and Pharmacovigilance (PhV) Inspections. During his tenure, he acted as: national expert to the European Medicines Agency (EMA); designated participant in the Emergency Task Force for COVID-19 products; chair of good PhV practices for the Spanish Technical Inspections Committee; member of the GCP Inspectors and PhV Inspectors working groups for the EMA; representative of AEMPS as a member of the Spanish GCP inspectors group; member of the working group of the International Coalition of Medical Regulatory Authorities. Dr. Vera-Sanchez's involvement in industry initiatives has led to important developments, including implementing critical aspects of inspections and guiding new PhV legislation. He also is an active participant in the FDA-EMA initiative, in which he: participated in the FDA's Bioresearch Monitoring training program (BIMO); conducted sponsor, clinical site and CRO inspections accompanied by FDA investigators; engaged in joint inspections where FDA and EMA practices were harmonized. "We are pleased to welcome a highly experienced senior regulator to our organization," said Mark A. Goldberg, M.D., executive chairman, CATO SMS. "Ernesto's extensive regulatory, GCP and pharmacovigilance knowledge will help provide our customers with independent and proactive quality assurance support to minimize regulatory risk while protecting the safety and well-being of study participants." Dr. Vera-Sanchez began his career as a primary care physician and specialist in anesthesiology. He holds a medical degree and dual master's degrees in public health and management of health institutions from the Universidad Autonoma de Madrid. He also earned a philosophus doctor degree in pharmacology and therapeutics from the Universidad de Valladolid. About CATO SMSCATO SMS is a provider of specialized clinical research solutions that was formed in 2019 when Cato Research merged with SMS-oncology. With more than 30 years of experience focusing on the needs of small and emerging biopharmaceutical companies, CATO SMS effectively designs and executes studies ⁠— from strategy to approval ⁠— in complex indications and modalities across a variety of therapeutic areas with a proven center of excellence in oncology. CATO SMS' regulatory, therapeutic and operational expertise enables the company to meet goals and exceed expectations. Visit  for more information. View original content:

Cato Research Frequently Asked Questions (FAQ)

  • When was Cato Research founded?

    Cato Research was founded in 1988.

  • Where is Cato Research's headquarters?

    Cato Research's headquarters is located at Westpark Corporate Center, Durham.

  • What is Cato Research's latest funding round?

    Cato Research's latest funding round is Merger.

  • Who are the investors of Cato Research?

    Investors of Cato Research include Allucent, Water Street Healthcare Partners and JLL Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.